Document is current
Any future updates will be listed below
-
Authors
Bannier, Pierre-Antoine https://orcid.org/0009-0008-1175-2976
Saillard, Charlie https://orcid.org/0000-0003-3061-839X
Mann, Philipp https://orcid.org/0000-0002-2857-4861
Touzot, Maxime
Maussion, Charles
Matek, Christian
Klümper, Niklas
Breyer, Johannes
Wirtz, Ralph
Sikic, Danijel
Schmitz-Dräger, Bernd
Wullich, Bernd
Hartmann, Arndt
Försch, Sebastian https://orcid.org/0000-0002-4740-6900
Eckstein, Markus https://orcid.org/0000-0001-5418-3349
- License Information
-
More Information
Article History
Received: 17 April 2024
Accepted: 9 December 2024
First Online: 30 December 2024
Competing interests
: Owkin employees own the company’s stocks (P.-A.B., C.S., M.T., P.M., C.M.). B.S-D: consultant for Arquer Ltd, UK, Cepheid, CA, USA, Concile GmbH, Germany, and Nucleix Inc., Israel. B.W.: received speaker’s honoraria from MSD and Janssen‐Cilag. N.K.: Personal fees, travel costs, and speaker’s honoraria from Astellas, Novartis, Ipsen, Photocure, MSD, BicycleTX; advisory role for BicycleTX; research funding from BicycleTX. A.H.: Honoraria for lectures for Abbvie, AstraZeneca, Biontech, BMS, Boehringer Ingelheim, Cepheid, Diaceutics, Ipsen, Janssen, Lilly, MSD, Nanostring, Novartis, Roche, 3DHistotech; Consulting/advisory role for Abbvie, AstraZeneca, Biontech, BMS, Boehringer Ingelheim, Cepheid, Diaceutics, Gilead, Illumina, Ipsen, Janssen, Lilly, MSD, Nanostring, Novartis, Qiagen, QUIP GmbH, Roche, 3DHistotech; research support from AstraZeneca, Biontech, Cepheid, Gilead, Illumina, Janssen, Nanostring, Qiagen, QUIP GmbH, Roche. M.E.: Personal fees, travel costs, and speaker’s honoraria from Eisai, MSD, AstraZeneca, Janssen-Cilag, Cepheid, Roche, Astellas, Diaceutics, Owkin, BMS, BicycleTX; research funding from AstraZeneca, Janssen-Cilag, STRATIFYER, Cepheid, Roche, Gilead, Owkin, QUIP GmbH, BicycleTX; advisory roles for Ferring, Diaceutics, MSD, AstraZeneca, Janssen-Cilag, GenomicHealth, Owkin, BMS, BicycleTX. R.M.W. is the CEO of STRATIFYER. All other authors declare no conflict of interest regarding the present work.
